The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
News|Articles|July 1, 2025
OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic therapeutic options that were cleared by the FDA in June 2025. The roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights contextualizing what they mean for clinical practice.
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Advertisement
Advertisement